{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-24-000045","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.282617+00:00","generated_at":"2026-06-02T08:39:51.050018+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Edwards Lifesciences annual meeting results: all four proposals approved by stockholders","bullets":["All eight director nominees elected with >447M 'for' votes each.","Advisory say-on-pay passed with 433M for vs 42M against.","Ratification of PwC as auditor for FY2024 approved (453M for, 53M against).","Amended long-term stock incentive compensation program approved (453M for, 21M against)."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-24-000045","json":"https://secwatch.observer/filing/0001099800-24-000045.json","markdown":"https://secwatch.observer/filing/0001099800-24-000045.md","text":"https://secwatch.observer/filing/0001099800-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/0001099800-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/ew-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:39:51.050018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61f0192ff71ac0b7b9d48310073fb86e7f63bf9a","claim":"Edwards Lifesciences Corp shareholders approved The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program at the 2024-05-07 meeting.","evidence_excerpt":"Proposal 4 : The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/0001099800-24-000045-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"d74e164d5e04ab6af72d2500b47df15453e70de0","claim":"Edwards Lifesciences Corp shareholders approved Election of Directors at the 2024-05-07 meeting.","evidence_excerpt":"All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/0001099800-24-000045-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"e13be40515624e91f4ebf66b9ab066b69492cb59","claim":"Edwards Lifesciences Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-07 meeting.","evidence_excerpt":"Proposal 3 : Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as set forth below:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/0001099800-24-000045-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-07"}],"fact_type":"shareholder_vote"},{"claim_id":"fb0081625c9b2e7b58515d0a8403cbf00c53ae66","claim":"Edwards Lifesciences Corp shareholders approved Advisory proposal regarding the Company’s named executive officer compensation at the 2024-05-07 meeting.","evidence_excerpt":"Proposal 2 : The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000045/0001099800-24-000045-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-05-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}